GS-4875
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 97 | 潰瘍性大腸炎 | 7 |
97. 潰瘍性大腸炎
臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
Showing 1 to 7 of 7 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-001430-33-DE (EUCTR) | 18/06/202020200618 | 25/02/202020200225 | A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitis A clinical trial to see if GS-4875is effective and safe in treating people with moderate to severe u ... | A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-48 ... | ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Code: GS-4875 Product Code: GS-4875 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Czech Republic;Canada;Belgium;Poland;Australia;Germany United States;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Czech Republic;Cana ... | ||
| 2 | EUCTR2019-001430-33-PL (EUCTR) | 20/05/202020200520 | 28/02/202020200228 | A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitis A clinical trial to see if GS-4875is effective and safe in treating people with moderate to severe u ... | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of ... | ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Code: GS-4875 Product Code: GS-4875 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Czech Republic;Canada;Poland;Belgium;Australia;Germany United States;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Czech Republic;Cana ... | ||
| 3 | EUCTR2019-001430-33-AT (EUCTR) | 15/05/202020200515 | 31/01/202020200131 | A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitis A clinical trial to see if GS-4875is effective and safe in treating people with moderate to severe u ... | A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-48 ... | Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Code: GS-4875 Product Code: GS-4875 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Czech Republic;Canada;Belgium;Poland;Australia;Germany United States;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Czech Republic;Cana ... | ||
| 4 | EUCTR2019-001430-33-GB (EUCTR) | 05/05/202020200505 | 21/02/202020200221 | A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitis A clinical trial to see if GS-4875is effective and safe in treating people with moderate to severe u ... | A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-48 ... | ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Code: GS-4875 INN or Proposed INN: to be confirmed Product Code: GS-4875 INN or Proposed INN: to be confirmed Product Code: GS-4875 INN or Proposed INN: to be confirmed Product Code: GS-4875 INN or Proposed INN: t ... | Gilead Sciences, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 2 | United States;Czechia;Austria;Russian Federation;United Kingdom;Italy;Switzerland;France;Canada;Belgium;Poland;Australia;Germany United States;Czechia;Austria;Russian Federation;United Kingdom;Italy;Switzerland;France;Canada;Belg ... | ||
| 5 | EUCTR2019-001430-33-IT (EUCTR) | 05/05/202020200505 | 27/01/202120210127 | A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitis A clinical trial to see if GS-4875is effective and safe in treating people with moderate to severe u ... | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis - FALCON A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of ... | ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ... | Product Name: GS-4875 Product Code: [GS-4875] Product Name: GS-4875 Product Code: [GS-4875] | GILEAD SCIENCES INCORPORATED | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Czechia;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Canada;Belgium;Poland;Australia;Germany United States;Czechia;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Canada;Belg ... | ||
| 6 | EUCTR2019-001430-33-FR (EUCTR) | 02/04/202020200402 | 20/02/202020200220 | A clinical trial to see if GS-4875 is effective and safe in treating people with moderate to severe ulcerative colitis A clinical trial to see if GS-4875is effective and safe in treating people with moderate to severe u ... | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of ... | ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Code: GS-4875 Product Code: GS-4875 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Czech Republic;Canada;Belgium;Poland;Australia;Germany United States;Austria;Russian Federation;Italy;Switzerland;United Kingdom;France;Czech Republic;Cana ... | ||
| 7 | NCT04130919 (ClinicalTrials.gov) | December 20, 201920191220 | 16/10/201920191016 | Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Activ ... | A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects With Moderately to Severely Active Ulcerative Colitis A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-48 ... | Ulcerative Colitis | Drug: Tilpisertib;Drug: Placebo | Gilead Sciences | NULL | Completed | 18 Years | N/A | All | 19 | Phase 2 | United States;Australia;Austria;Canada;France;Germany;Italy;Poland;Switzerland |